Breaking News

AGC Triples U.S. Biopharma Production Capacity

Will invest $90 million to expand animal cell bioreactors and add new microorganism facilities

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AGC Biologics has enhanced its production capacity of biopharmaceutical manufacturing services. The contract development and manufacturing organization (CDMO) plans to install an additional twelve 2,000L single-use animal cell bioreactors at their Seattle, WA site, as well as establish a brand new contract development and manufacturing facility for microbial manufacturing, a function that was previously only operated in Europe and Japan.    This expansion will triple AGC’s biopharmaceu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters